Explore

Companies

Drugs

VivoSeq

About·Data Management·Terms·Privacy

Stay informed

Oncology/Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8

Oncology

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 is an early-stage landscape with 8 programs across 6 companies. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical4

Atezolizumab

Roche

Bevacizumab

Roche

Cetuximab

Imclone

Docetaxel

Avyxa

Phase 1

No programs

Phase 21

Cemiplimab

Regeneron

Phase 33

Paclitaxel

Teva

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Carboplatin

Avyxa

Approved

No programs

Analysis

Modality Breakdown

8programs

Small molecule450%

Monoclonal antibody450%

Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

clinical trials

Active, not recruiting3 · 75%

Recruiting1 · 25%

Clinical Trials

Trial Activity

Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma

Active, not recruiting·ECOG-ACRIN Cancer Research Group·Phase 3·NCT05721755·290 enrolled

A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers

Active, not recruiting·National Cancer Institute (NCI)·Preclinical·NCT05063552·430 enrolled

Ototoxicity Monitoring and Remote Audiometry

Recruiting·EEmory University·Preclinical·NCT06662058·118 enrolled

A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting·—·Phase 2·NCT04862650·46 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)